Antibiotic Pharmacokinetic/Pharmacodynamic Considerations in the Critically Ill
https://libcat.nshealth.ca/en/permalink/provcat43083
Andrew A. Udy, Jason A. Roberts, Jeffrey Lipman, editors.
--Singapore:
Adis
, c2018.
- Available Online
- View e-Book
- Location
- Online
This book provides unique insights into the issues that drive modified dosing regimens for antibiotics in the critically ill. Leading international authors provide their commentary alongside a summary of existing evidence on how to effectively dose antibiotics. Severe infection frequently necessitates admission to the intensive care unit (ICU). Equally, nosocomial sepsis often complicates the clinical course in ICU. Early, appropriate application of antibiotic therapy remains a cornerstone of e…
- Available Online
- View e-Book
- Other Authors
- Udy, Andrew A.
- Roberts, Jason A.
- Lipman, Jeffrey
- Responsibility
- Andrew A. Udy, Jason A. Roberts, Jeffrey Lipman, editors
- Place of Publication
- Singapore
- Publisher
- Adis
- Date of Publication
- c2018
- Physical Description
- 1 online resource (x, 275 p.) : 22 illus., 9 illus. in color
- ISBN
- 9789811053368
- 9789811053351 (print ed.)
- 9789811053375 (print ed.)
- Subjects (MeSH)
- Anti-Bacterial Agents - administration & dosage
- Anti-Bacterial Agents - pharmacokinetics
- Comparative Effectiveness Research
- Critical Illness - therapy
- Treatment Outcome
- Specialty
- Critical Care
- Pharmacology
- Abstract
- This book provides unique insights into the issues that drive modified dosing regimens for antibiotics in the critically ill. Leading international authors provide their commentary alongside a summary of existing evidence on how to effectively dose antibiotics. Severe infection frequently necessitates admission to the intensive care unit (ICU). Equally, nosocomial sepsis often complicates the clinical course in ICU. Early, appropriate application of antibiotic therapy remains a cornerstone of effective management. However, this is challenging in the critical care environment, given the significant changes in patient physiology and organ function frequently encountered. Being cognisant of these factors, prescribers need to consider modified dosing regimens, not only to ensure adequate drug exposure, and therefore the greatest chance of clinical cure, but also toáavoid encouraging drug resistance.
- Contents
- 1. Basic Pharmacokinetic Principles -- 2. Antibiotic Pharmacodynamics -- 3. Physiological Manifestations of Critical Illness -- 4. Dosing in Obese Critically Ill Patients -- 5. Hypoalbuminemia and Altered Protein Binding -- 6. Antibacterial Pharmacokinetic/Pharmacodynamic Considerations in the Critically ill -- 7. Augmented Renal Clearance -- 8. Antibiotic Dosing During Extracorporeal Membrane Oxygenation -- 9. Therapeutic Drug Monitoring: More than Avoiding Toxicity -- 10. Generic and Optimised Antibacterial Dosing Strategies in the Critically Ill -- 11. Antifungal PK/PD in the Critically Ill -- 12. Antibiotic Dosing in Pediatric Critically Ill Patients -- 13. Antibiotic Stewardship in the Intensive Care Unit.
- Format
- e-Book
- Location
- Online
Antiepileptic Drug Interactions : A Clinical Guide
https://libcat.nshealth.ca/en/permalink/provcat40233
Philip N. Patsalos.
(3rd ed.)
--Cham:
Springer
, c2016.
- Available Online
- View e-Book
- Location
- Online
This updated third edition of a successful book is a description of both pharmacokinetic and pharmacodynamic antiepileptic drug (AED) interactions, including details of the magnitude and mechanism of interactions, and also of drug combinations that are not associated with interactions and therefore can be coprescribed without undue concern. Presented in alphabetical order and by drug class, drug interactions that occur between AEDs and also between AEDs and non-AEDs are described in three secti…
- Available Online
- View e-Book
- Author
- Patsalos, Philip N
- Responsibility
- Philip N. Patsalos
- Edition
- 3rd ed.
- Place of Publication
- Cham
- Publisher
- Springer
- Date of Publication
- c2016
- Physical Description
- 1 online resource (xlix, 340 p. : 31 illus.)
- ISBN
- 9783319329093
- 9783319329086 (print ed.)
- Subjects (MeSH)
- Anticonvulsants
- Drug Interactions
- Epilepsy - drug therapy
- Abstract
- This updated third edition of a successful book is a description of both pharmacokinetic and pharmacodynamic antiepileptic drug (AED) interactions, including details of the magnitude and mechanism of interactions, and also of drug combinations that are not associated with interactions and therefore can be coprescribed without undue concern. Presented in alphabetical order and by drug class, drug interactions that occur between AEDs and also between AEDs and non-AEDs are described in three sections: Drug interactions between AEDs; Drug interactions between AEDs and non-AED Drugs: Interactions affecting AEDs; Drug interactions between AEDs and non-AED Drugs: Interactions affected by AEDs. Antiepileptic Drug Interactions: A Clinical Guide, 3rd Edition with its clear, concise and unambiguous content will allow physicians and allied health professionals to make more rational choices when AED polytherapy regimens are indicated. There is always a choice and avoiding highly interacting drugs and choosing drug combinations that are minimally interacting or do not interact should be the goal in treating patients with epilepsy. This book provides all the necessary information so as to allow this goal to be achieved and, if necessary, to aid effective management of AED interactions.
- Contents
- Section 1: Introduction -- Section 2: Drug Interactions Between AEDs -- Acetazolamide -- Carbamazepine -- Clobazam -- Clonazepam -- Ethosuximide -- Eslicarbazepine acetate -- Felbamate -- Gabapentin -- Lacosamide -- Lamotrigine -- Levetiracetam -- Methsuximide -- Oxcarbazepine -- Perampanel -- Phenobarbital -- Phenytoin -- Piracetam -- Pregabalin -- Primidone -- Retigabine -- Rufinamide -- Stiripentol -- Tiagabine -- Topiramate -- Valproic Acid -- Vigabatrin -- Zonisamide -- Section 3: Drug Interactions between AEDs and non-AED drugs: Interactions Affecting AEDs -- Acetazolamide -- Carbamazepine -- Clobazam -- Clonazepam -- Ethosuximide -- Eslicarbazepine acetate -- Felbamate -- Gabapentin -- Lacosamide -- Lamotrigine -- Levetiracetam -- Methsuximide -- Oxcarbazepine -- Perampanel -- Phenobarbital -- Phenytoin -- Piracetam -- Pregabalin -- Primidone -- Retigabine -- Rufinamide -- Stiripentol -- Tiagabine -- Topiramate -- Valproic Acid -- Vigabatrin -- Zonisamide -- Section 4: Drug Interactions between AEDs and non-AED drugs: Interactions Affected by AEDS -- Analgesics -- Antimicrobials -- Antineoplastic agents -- Antiulcer drugs -- Cardiovascular drugs -- Immunosuppressants -- Neuromuscular Blocking Agents -- Psychotropic Drugs -- Steroids -- Miscellanea.
- Format
- e-Book
- Location
- Online
Antiepileptic Drugs and Pregnancy : A Guide for Prescribers
https://libcat.nshealth.ca/en/permalink/provcat39849
MJ Eadie, FJE Vajda.
--Cham:
Springer International Publishing : Imprint: Adis
, c2016.
- Available Online
- View e-Book
- Location
- Online
A description of our current understanding of antiepileptic drug use during pregnancy, this book includes chapters on the impact of seizures on the mother and developing child, changes in maternal physiology during pregnancy and its impact on drug disposition, and the pharmacokinetic differences between the various anti-seizure medications. It also deals with the possible harmful effects of antiepileptic drug exposure during pregnancy on the physical and intellectual development of the fetus. C…
- Available Online
- View e-Book
- Author
- Eadie, MJ
- Other Authors
- Vajda, FJE
- Responsibility
- MJ Eadie, FJE Vajda
- Place of Publication
- Cham
- Publisher
- Springer International Publishing : Imprint: Adis
- Date of Publication
- c2016
- Physical Description
- 1 online resource (xii, 232 p. : 24 illus., 6 illus. in color)
- ISBN
- 9783319214344
- 9783319214337 (print ed.)
- Subjects (MeSH)
- Anticonvulsants
- Epilepsy - drug therapy
- Pregnancy Complications
- Pregnancy
- Abstract
- A description of our current understanding of antiepileptic drug use during pregnancy, this book includes chapters on the impact of seizures on the mother and developing child, changes in maternal physiology during pregnancy and its impact on drug disposition, and the pharmacokinetic differences between the various anti-seizure medications. It also deals with the possible harmful effects of antiepileptic drug exposure during pregnancy on the physical and intellectual development of the fetus. Clinicians have to balance the potential adverse effects of the medicine for the fetus and mother-to-be against the risks that uncontrolled seizures hold for both when treating pregnant women with antiepileptic drugs. Only recently have enough scientific data emerged to provide a rational basis for treatment decisions that take in both aspects. This work provides a single, accessible, and up-to-date resource for busy clinicians.
- Contents
- 1. Introduction -- 2. Antiepileptic drugs and becoming pregnant -- Part I: Antiepileptic Drug Pharmacokinetics in Pregnancy -- 3. Antiepileptic drug disposition and pregnancy -- 4. The older antiepileptic drugs -- 5. Commonly used newer antiepileptic drugs -- 6. Antiepileptic drugs sometimes used in pregnancy -- Part II: Antiepileptic Drugs and the Foetus -- 7. Antiepileptic drugs, epileptic seizures and the foetus -- 8. Antiepileptic drugs and foetal malformations - a possible class effect -- 9. Particular antiepileptic drugs and foetal malformations -- 10. Antiepileptic drugs, cognition and neurodevelopment -- Part III: Antiepileptic Drug use and Pregnancy -- 11. Antiepileptic drug therapy: management issues and pregnancy -- 12. Antiepileptic drugs and pregnancy: the future.
- Format
- e-Book
- Location
- Online
Antiepileptic drugs : combination therapy and interactions
https://libcat.nshealth.ca/en/permalink/provcat27219
Majkowski, Jerzy.
--Cambridge, UK:
Cambridge University Press
, c2005.
- Available Online
- View e-Book
- Location
- Online
- Available Online
- View e-Book
- Author
- Majkowski, Jerzy
- Place of Publication
- Cambridge, UK
- Publisher
- Cambridge University Press
- Date of Publication
- c2005
- Physical Description
- 496 p.
- ISBN
- 6610202834
- Contents
- Cover -- Half-title -- Title -- Copyright -- Contents -- List of contributors -- Foreword -- Foreword -- Acknowledgements -- Part I Introduction -- 1 Combination therapy of diseases: general concepts -- Historical aspects -- Polypharmacy -- Polytherapy -- Epidemiology of combination therapy -- Advantages of combination therapy -- Disadvantages of combination therapy -- Conclusions -- REFERENCES -- 2 Combination therapy with antiepileptic drugs: potential advantages and problems -- Rationale for combination therapy -- Potential advantages of combination therapy -- Evidence of benefits of combination therapy versus monotherapy -- Potential problems with combined AEDs -- Summary -- REFERENCES -- 3 Pharmacogenetic aspects -- Introduction -- Metabolism -- Central pharmacokinetics -- Pharmacodynamics -- Adverse events -- Misconceptions about the use of genetic tests -- REFERENCES -- Part II Pharmacokinetic interactions -- 4 Pharmacokinetic principles and mechanisms of drug interactions -- Introduction -- Mechanisms of drug interactions -- Absorption -- Distribution -- Metabolism -- Elimination -- REFERENCES -- 5 Predictability of metabolic antiepileptic drug interactions -- Principles of drug metabolism -- Major drug-metabolizing enzymes -- Enzyme induction and enzyme inhibition -- In vitro systems for testing drug metabolism and metabolic drug interactions -- Prediction of metabolic drug interactions based on in vitro data -- Crucial factors in predicting in vitro-in vivo correlations -- Conclusions -- REFERENCES -- 6 Influence of food and drugs on the bioavailability of antiepileptic drugs -- Introduction -- General principles -- Interactions with the established AEDs -- Interactions with other AEDs -- REFERENCES -- 7 Interactions between antiepileptic drugs -- Summary -- Introduction -- Interactions between classic AEDs (phenobarbital, phenytoin, primidone, carbamazepine, valproic acid, ethosuximide, methsuximide) and other AEDs -- Interactions between new AEDs and other AEDs -- Therapeutic implications -- REFERENCES -- 8 Interaction between antiepileptic and non-antiepileptic drugs -- Introduction -- Carbamazepine -- Ethosuximide -- Felbamate -- Gabapentin -- Lamotrigine -- Levetiracetam -- Oxcarbazepine -- Phenobarbital -- Phenytoin -- Primidone -- Tiagabine -- Topiramate -- Valproic acid -- Vigabatrin -- Zonisamide -- REFERENCES -- Part III Pharmacodynamic interactions -- 9 Pharmacodynamic principles and mechanisms of drug interactions -- Distinction between pharmacodynamic and pharmacokinetic drug interactions -- Types of pharmacodynamic interaction -- Clinical significance of pharmacodynamic interactions -- Desirable and undesirable pharmacodynamic interactions -- Clinical relevance of pharmacodynamic interactions: monotherapy versus combination therapy -- REFERENCES -- 10 Methods for assessing pharmacodynamic interactions -- Experimental methods -- Clinical methods -- REFERENCES -- 11
- Format
- e-Book
- Location
- Online
Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents
https://libcat.nshealth.ca/en/permalink/provcat40067
Michael W. Jann, Scott R. Penzak, Lawrence J. Cohen, editors.
(1st ed.)
--Cham:
Springer International Publishing : Imprint: Adis
, c2016.
- Available Online
- View e-Book
- Location
- Online
This book is a comprehensive resource on psychotropic medications, detailing the latest methods for defining their characteristics, their use in different patient populations, and drug-drug interactions; an important collection of information for clinicians, students, researchers, and members of the pharmaceutical industry alike. The first section provides the foundational principles of these drugs. Mathematical modeling of parameters that affect their entryto,and exit from, the central nervous…
- Available Online
- View e-Book
- Other Authors
- Jann, Michael W
- Penzak, Scott R
- Cohen, Lawrence J
- Responsibility
- Michael W. Jann, Scott R. Penzak, Lawrence J. Cohen, editors
- Edition
- 1st ed.
- Place of Publication
- Cham
- Publisher
- Springer International Publishing : Imprint: Adis
- Date of Publication
- c2016
- Physical Description
- 1 online resource (xiv, 601 p. : 100 illus., 50 illus. in color)
- ISBN
- 9783319278834
- 9783319278810 (print ed.)
- Subjects (MeSH)
- Drug Interactions
- Psychotropic Drugs - pharmacokinetics
- Psychotropic Drugs - pharmacology
- Abstract
- This book is a comprehensive resource on psychotropic medications, detailing the latest methods for defining their characteristics, their use in different patient populations, and drug-drug interactions; an important collection of information for clinicians, students, researchers, and members of the pharmaceutical industry alike. The first section provides the foundational principles of these drugs. Mathematical modeling of parameters that affect their entryto,and exit from, the central nervous system (CNS) compartment are presented on an individual basis and then applied to target populations with specific disease states. Methods and characteristics that inform the transfer of these drugs from the laboratory bench to use in patient care are discussed, including imaging techniques, genetics and physiological barriers, such as the blood-brain barrier. The second section describes the characteristics of specific agents,nominally arranged intodifferent therapeutic categories and with reference crossover use in different disease states. The pharmacologic characteristics of different drug formulations are explored in the context of their ability to improve patient adherence. The third section focuses on drug-drug interactions.Psychotropic medications from different categories are frequently prescribed together, or alongside medications used to treat comorbid conditions, and the information provided is directly relevant to the clinic, as a result. The clinical application of pharmacokinetics and pharmacodynamics of CNS agents has made significant progress over the past 50 years and new information is reported by numerous publications in psychiatry, neurology, and pharmacology. Our understanding of the interrelationship between these medications, receptors, drug transporters, as well as techniques for measurement and monitoring their interactions, is frequently updated. However, with information presented on a host of different platforms, and in different formats, obtaining the full picture can be difficult. This title aims to collate this information into a single source that can be easily interpreted and applied towards patient care by the clinical practitioner, and act as a reference for all others who have an interest in psychopharmacological agents.
- Contents
- Section 1. General Pharmacokinetic and Pharmacodynamic Principles of Psychopharmacological Agents -- 1. Pharmacokinetic Properties -- 2. Pharmacodynamic Properties -- 3. PET Scan and Other Biomarkers -- 4. Population Pharmacokinetics -- 5. Drug Transporters (esp. Blood Brain Barrier) -- 6. Pharmacogenomics -- Section 2. Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Drug Classes -- 7. Antipsychotics: oral typical agents, oral atypical agents, and long-acting injectable (LAI) antipsychotics -- 8. Mood Stabilizers -- 9. Antidepressants: tricyclics, selective serotonergic reuptake inhibitors, serotonergic noradrenergic reuptake inhibitors, monoamine oxidase inhibitors, and other antidepressants -- 10. Benzodiazepines and Other Sedative Hypnotics/Anxiolytics -- 11. Opioid Analgesics -- 12. Stimulants and Other Non-Stimulants for ADHD -- 13. Cholinesterase Inhibitors and Other Antidementa Agents -- 14. Anti-Addiction Agents -- 15. Anesthetics -- Section 3. Clinically Significant Drug Interactions With Psychopharmacological Agents -- 16. Antipsychotics -- 17. Mood Stabilizers -- 18. Antidepressants -- 19. Benzodiazepines and Other Sedative Hypnotics/Anxiolytics -- 20. Opioid Analgesics -- 21. Stimulants and Other Non-Stimulants for ADHD -- 22. Cholinesterase Inhibitors and Other Antidementa Agents -- 23. Anti-Addiction Agents -- 24. Anesthetics.
- Format
- e-Book
- Location
- Online
A Case Approach to Perioperative Drug-Drug Interactions
https://libcat.nshealth.ca/en/permalink/provcat38917
Catherine Marcucci, Michael P. Hutchens, Erica D. Wittwer, Toby N. Weingarten, Juraj Sprung, Wayne T. Nicholson, Kirk Lalwani, David G. Metro, Randal O. Dull, Christopher E. Swide, F. Jacob Seagull, Jeffrey R. Kirsch, Neil B. Sandson, editors.
--New York, NY:
Springer
, c2015.
- Available Online
- View e-Book
- Location
- Online
The occurrence of deleterious or even fatal drug-drug interactions (DDIs) in the perioperative period is no longer a theoretical concern but a harrowing reality. A Case Approach to Perioperative Drug-Drug Interactions addresses the complex realm of pharmacokinetic drug interactions in an easy-to-read volume that functions as both a comprehensive clinical reference and a casebook. The book presents a summary of the core concepts of drug interactions; an organized, annotated presentation of the d…
- Available Online
- View e-Book
- Other Authors
- Marcucci, Catherine
- Hutchens, Michael P
- Wittwer, Erica D
- Weingarten, Toby N
- Sprung, Juraj
- Nicholson, Wayne T
- Lalwani, Kirk
- Metro, David G
- Dull, Randal O
- Swide, Christopher E
- Seagull, F. Jacob
- Kirsch, Jeffrey R
- Sandson, Neil B
- Responsibility
- Catherine Marcucci, Michael P. Hutchens, Erica D. Wittwer, Toby N. Weingarten, Juraj Sprung, Wayne T. Nicholson, Kirk Lalwani, David G. Metro, Randal O. Dull, Christopher E. Swide, F. Jacob Seagull, Jeffrey R. Kirsch, Neil B. Sandson, editors
- Place of Publication
- New York, NY
- Publisher
- Springer
- Date of Publication
- c2015
- Physical Description
- 1 online resource (xliv, 1016 p. : 45 illus., 16 illus. in color)
- ISBN
- 9781461474951
- 9781461474944 (print ed.)
- Subjects (MeSH)
- Drug Interactions
- Perioperative Period
- Abstract
- The occurrence of deleterious or even fatal drug-drug interactions (DDIs) in the perioperative period is no longer a theoretical concern but a harrowing reality. A Case Approach to Perioperative Drug-Drug Interactions addresses the complex realm of pharmacokinetic drug interactions in an easy-to-read volume that functions as both a comprehensive clinical reference and a casebook. The book presents a summary of the core concepts of drug interactions; an organized, annotated presentation of the drug interactions most relevant to the perioperative clinician; and approximately 200 case scenarios that highlight specific drug interactions. This book fills a real void in the clinical literature and is invaluable to anesthesiologists and surgeons, and PharmDs, as well as trainees in those specialties; intensive care staff, including physicians, physician assistants, and nurses; and nurse practitioners who staff preoperative evaluation clinics.
- Contents
- Part I. Introduction to Drug–Drug Interactions -- Part II. Introduction to Drug–Drug Interactions: Brief Review of Cytochrome P450 (CYP450) Enzymes, Uridine 5’-diphosphoglucuronoslytransferases (UGTs), and Transporters -- Part III. Drug–Drug Interactions: Paradigms and Core Concepts -- Part IV. Drug–Drug Interactions Involving Inhalational Anesthetic Agents -- Part V. Drug–Drug Interactions Involving Intravenous Anesthetic Agents -- Part VI. Drug–Drug Interactions Involving Local Anesthetics -- Part VII. Drug–Drug Interactions Involving Opioids -- Part VIII. Drug–Drug Interactions Involving Non opioid Pain Medications -- Part IX. Drug–Drug Interactions Involving Benzodiazepines and Other Sedatives -- Part X. Drug–Drug Interactions Involving Neuromuscular Blockade Agents -- Part XI. Drug–Drug Interactions Involving Antibiotics and Antifungals -- Part XII. Drug–Drug Interactions Involving Cardiovascular Medications -- Part XIII. Drug–Drug Interactions Involving Coagulation Modifiers -- Part XIV. Drug–Drug Interactions Involving Immunosuppressants, Antiemetics, and Chemotherapy -- Part XV. Drug–Drug Interactions Involving Neuropsychiatric Drugs -- Part XVI. Drug–Drug Interactions Involving QT-Prolonging DDIs -- Part XVII. Drug–Drug Interactions Involving Foods and Nutrition -- Part XVIII. Drug–Drug Interactions Involving Spices and Supplements -- Fatal Forty Index -- Drug Index (Generic) --- Drug Index (Brand).
- Format
- e-Book
- Publication Type
- Case Reports
- Location
- Online
Clinical pharmacokinetic and pharmacodynamic drug interactions associated with antimalarials
https://libcat.nshealth.ca/en/permalink/provcat33949
Tony K.L. Kiang, Kyle John Wilby, Mary H.H. Ensom.
--Cham, Switzerland:
Adis
, c2015.
- Available Online
- View e-Book
- Location
- Online
This comprehensive review provides a systematic, unbiased analysis, critique and summary of the available literature and generates novel clinical decision-making algorithms which can aid clinicians and scientists in practice management and research development. Potential mechanisms for the identified drug interactions are deduced from available preclinical and in vitro data which are interpreted in the context of the in vivo findings. Current limitations and gaps in the literature are summarize…
- Available Online
- View e-Book
- Author
- Kiang, Tony K. L
- Other Authors
- Wilby, Kyle John
- Ensom, Mary H.H.
- Responsibility
- Tony K.L. Kiang, Kyle John Wilby, Mary H.H. Ensom
- Place of Publication
- Cham, Switzerland
- Publisher
- Adis
- Date of Publication
- c2015
- Physical Description
- 1 online resource (vii, 146 pages)
- ISBN
- 9783319105277 (electronic bk.)
- 9783319105260
- Subjects (MeSH)
- Antimalarials - pharmacokinetics
- Drug interactions
- Malaria - drug therapy
- Abstract
- This comprehensive review provides a systematic, unbiased analysis, critique and summary of the available literature and generates novel clinical decision-making algorithms which can aid clinicians and scientists in practice management and research development. Potential mechanisms for the identified drug interactions are deduced from available preclinical and in vitro data which are interpreted in the context of the in vivo findings. Current limitations and gaps in the literature are summarized, and potential future research directions / experimentations are also suggested. In addition to the main objective to review the available clinical pharmacokinetic and pharmacodynamic drug interactions associated with WHO-recommended antimalarial drugs on the market today (i.e. chloroquine, amodiaquine, sulfadoxine, pyrimethamine, mefloquine, artemisinin, artemether, artesunate, dihydroartemisinin, artemotil, lumefantrine, primaquine, atovaquone, proguanil, piperaquine and quinine), this book also provides succinct chapter summaries on the epidemiology of malaria infection, diagnosis and therapeutics, in vivo pharmacology and chemistry, preclinical pharmacology, in vitro pharmacodynamics, in vitro reaction phenotyping, and in vitro drug-drug interaction data associated with the identified antimalarial drugs.
- Contents
- Introduction -- Pharmacology of Recommended Antimalarial Agents -- Drug Interaction Potential of Antimalarial Drugs Based on Known Metabolic Properties of Antimalarials -- Pharmacokinetic Drug Interactions Affecting Antimalarials -- Effects of Antimalarials on the Pharmacokinetics of Co-Administered Drugs -- Effects of Antimalarials on the Pharmacokinetics of Co-Administered Antimalarials -- Pharmacodynamic Interactions: Clinical Evidence for Combination Therapy, In Vitro Interactions, and In Vivo Interactions -- Limitations, Future Directions, and Conclusions.
- Format
- e-Book
- Location
- Online
Clinical psychopharmacology : a practical approach
https://libcat.nshealth.ca/en/permalink/provcat31339
Humberto Marin, Javier I Escóbar.
--Hackensack, NJ:
World Scientific Pub. Co
, c2013.
- Available Online
- View e-Book
- Location
- Online
This book aims to provide comprehensive, up-to-date information on psychotropic drugs and inform clinical decisions for the treatment of mental disorders using a problem-solving approach. In order to accomplish these goals, the book has three central characteristics: it is evidence-based; it compares each individual drug with others in the same class and also those used for the same indications rather than describing them separately; it steadily draws practical conclusions and makes recommendat…
- Available Online
- View e-Book
- Author
- Marin, Humberto
- Other Authors
- Escóbar, Javier I
- Responsibility
- Humberto Marin, Javier I Escóbar
- Place of Publication
- Hackensack, NJ
- Publisher
- World Scientific Pub. Co
- Date of Publication
- c2013
- Physical Description
- 1 online resource (286 p.)
- ISBN
- 9789814343664
- Subjects (MeSH)
- Mental Disorders - drug therapy
- Psychopharmacology
- Psychotropic Drugs
- Abstract
- This book aims to provide comprehensive, up-to-date information on psychotropic drugs and inform clinical decisions for the treatment of mental disorders using a problem-solving approach. In order to accomplish these goals, the book has three central characteristics: it is evidence-based; it compares each individual drug with others in the same class and also those used for the same indications rather than describing them separately; it steadily draws practical conclusions and makes recommendations about how to select and use medications in the treatment of specific mental disorders. More than a textbook, it is meant to serve as a practical tool for professionals working in the mental health field.
- Contents
- Ch. 1. Absorption, transformation, and elimination of psychotropic medications. -- ch. 2. Neurotransmitters, receptors, and transporters. 2.1. Main types of receptors in the brain. 2.2. Neurotransmitters. 2.3. Neurotransmitter reuptake transporters -- ch. 3. Antipsychotics: a general view of therapeutic and adverse effects. 3.1. Classic antipsychotics. 3.2. New antipsychotics. 3.3. Are the new antipsychotics clinically different from the old ones? 3.4. Current concepts regarding antipsychotic action and the D[symbol] receptor. 3.5. Comparison between typical and atypical antipsychotics. 3.6. Metabolic side effects of antipsychotic drugs. 3.7. Extrapyramidal symptoms of antipsychotics. 3.8. Neuroleptic malignant syndrome. 3.9. Catatonia. 3.10. Antipsychotic-induced hyperprolactinemia. 3.11. Sexual side effects of antipsychotics. 3.12. Antihistamine adverse effects of antipsychotics. 3.13. Anticholinergic adverse effects of antipsychotics: cognitive and peripheral. 3.14. Antipsychotics and the risk of seizures. 3.15. Vascular side effects of antipsychotics. 3.16. Antipsychotics and the risk of malignant arrythmia and sudden cardiac death. 3.17. Antipsychotics and increased morbidity and mortality in patients with dementia. 3.18. Antipsychotics and suicide. 3.19. Antipsychotics and the risk of cancer -- ch. 4. Description of individual antipsychotics. 4.1. Typical antipsychotics. 4.2. Atypical antipsychotics -- ch. 5. Treatment of schizophrenia with antipsychotic medications. 5.1. Choice of an antipsychotic for the initial treatment of schizophrenia. 5.2. Dosing in the initial antipsychotic treatment of schizophrenia. 5.3. How long does it take to respond to an antipsychotic? 5.4. Monitoring antipsychotic treatment. 5.5. Maintenance of antipsychotic treatment of schizophrenia. 5.6. Combination of antipsychotic drugs in schizophrenia ("polypharmacy"). 5.7. Pharmacological management of treatment-resistant schizophrenia. 5.8. Use of long-acting injectable antipsychotics in schizophrenia -- ch. 6. Antidepressants: selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors. 6.1. Introduction. 6.2. Pharmacodynamics of SSRIs and SNRIs (receptor affinity). 6.3. Pharmacokinetics of SSRIs and SNRIs. 6.4. Use of SSRIs in mental disorders. 6.5. Use of SNRIs in mental disorders. 6.6. Dosing of SSRIs and SNRIs. 6.7. Adverse effects of SSRIs and SNRIs. 6.8. Discontinuation syndrome with SSRIs and SNRIs. 6.9. Toxicity of SSRIs and SNRIs and serotonin syndrome. 6.10. Precautions with SSRIs and SNRIs. 6.11. Use of SSRIs and SNRIs during pregnancy and lactation -- ch. 7. Bupropion. 7.1. Introduction. 7.2. Pharmacology. 7.3. Approved indications and other possible uses. 7.4. Dosing and available forms of bupropion. 7.5. Side effects and adverse reactions. 7.6. Contraindications, warnings, and precautions. 7.7. Use of bupropion during pregnancy -- Ch. 8. Mirtazapine, trazodone, and nefazodone. 8.1. Mirtazapine. 8.2. Trazodone. 8.3. Nefazodone -- ch. 9. Monoamine oxidase inhibitors and tricyclic antidepressants. 9.1. Monoamine oxidase inhibitors. 9.2. Tricyclic antidepressants -- ch. 10. Individualized treatment of depression. 10.1. Patient factors to consider. 10.2. Second-generation antidepressants: doses and duration. 10.3. Hypnotics and other symptom-specific medications. 10.4. Partial response to antidepressant treatment: what to do? 10.5. No response to initial antidepressant treatment: what to do? 10.6. What about adding atypical antipsychotics in the initial treatment of depression? 10.7. Other non-antidepressant drugs recently tried in depression. 10.8. Once the patient gets better, how to stop antidepressant treatment? -- ch. 11. Benzodiazepines, buspirone, and miscellaneous medications used in anxiety disorders. 11.1. Benzodiazepines. 11.2. Buspirone. 11.3. Antiepileptic drugs. 11.4. Antihistamines. 11.5. Prazosin for nightmares in post-traumatic stress disorder. 11.6. Do antipsychotics have a role in anxiety? 11.7. Beta-blockers -- ch. 12. Medication treatment of anxiety disorders. General considerations prior to starting drug treatment. Other considerations. 12.1. Approved and potential uses of antidepressants and other medications. 12.2. Drug treatment of individual anxiety disorders -- ch. 13. Medications used in the treatment of mania. 13.1. Lithium. 13.2. Antipsychotics. 13.3. Carbamazepine. 13.4. Oxcarbazepine. 13.5. Valproic acid (divalproex, valproate). 13.6. Tamoxifen -- ch. 14. Medications used in bipolar depression, mixed states, and rapid cycling. 14.1. Electroconvulsive therapy. 14.2. Lithium. 14.3. Quetiapine. 14.4. Lamotrigine. 14.5. Valproate. 14.6. Antidepressants. 14.7. Ketamine in bipolar and treatment-resistant depression. 14.8. Pharmacological treatment of mixed states and rapid cycling bipolar disorder -- ch. 15. Medications used in the treatment of insomnia. 15.1. General rules. 15.2. Antihistamines as hypnotics. 15.3. Sedating antidepressants (trazodone and mirtazapine). 15.4. Melatonin receptor agonists. 15.5. GABA receptor agonists -- ch. 16. Medications used in the treatment of attention disorders. 16.1. Stimulant medications (psychostimulants). 16.2. Atomoxetine. 16.3. Bupropion. 16.4. Modafinil. 16.5. [symbol]-adrenergic agonists (guanfacine and clonidine) -- ch. 17. Medications used in the treatment of dementia. 17.1. Side effects. 17.2. Pharmacokinetics. 17.3. Pointers for clinical use -- ch. 18. Medications used in smoking cessation and alcohol use disorders. 18.1. Medications used in the treatment of nicotine dependence (smoking cessation). 18.2. Medications used in the treatment of alcohol use disorders -- ch. 19. Drug-drug interactions. 19.1. Pharmacokinetic drug-drug interactions. 19.2. Pharmacodynamic DDIs involving psychotropic drugs. 19.3. Drug-drug Interactions due to cumulative toxicity. 19.4. Drug-drug interactions related to food supplements and substances of abuse.
- Format
- e-Book
- Location
- Online
Development of Antibody-Based Therapeutics : Translational Considerations
https://libcat.nshealth.ca/en/permalink/provcat30858
Mohammad A. Tabrizi, Gadi G. Bornstein, Scott L. Klakamp, editors.
--New York, NY:
Springer
, c2012.
- Available Online
- View e-Book
- Location
- Online
Development of Antibody-Based Therapeutics: Translational Considerations examines important considerations necessary for the design of effective translational strategies during the development of antibody-based therapeutics. Translational strategies for development of antibody-based therapeutics require an understanding of the relationship between the 'unit dose' and 'unit effect' with respect to both beneficial and deleterious biological effects from early stages of development. The flow of in…
- Available Online
- View e-Book
- Other Authors
- Tabrizi, Mohammad A
- Bornstein, Gadi G
- Klakamp, Scott L
- Responsibility
- Mohammad A. Tabrizi, Gadi G. Bornstein, Scott L. Klakamp, editors
- Place of Publication
- New York, NY
- Publisher
- Springer
- Date of Publication
- c2012
- Physical Description
- 1 online resource (xiv, 425 p. : 58 ill., 30 ill. in color)
- ISBN
- 9781441959553
- Subjects (MeSH)
- Antibodies, Monoclonal - pharmacology
- Antibodies, Monoclonal - therapeutic use
- Antigens - immunology
- Drug Discovery
- Translational Medical Research
- Subjects (LCSH)
- Pharmacy
- Biochemistry
- Immunology
- Abstract
- Development of Antibody-Based Therapeutics: Translational Considerations examines important considerations necessary for the design of effective translational strategies during the development of antibody-based therapeutics. Translational strategies for development of antibody-based therapeutics require an understanding of the relationship between the 'unit dose' and 'unit effect' with respect to both beneficial and deleterious biological effects from early stages of development. The flow of information across various stages of development should provide opportunities to facilitate selection of more effective novel and next-generation drug candidates. Successful strategies for the development of monoclonal antibodies require integration of knowledge with regards to target antigen properties in health and disease, as well as antibody design criteria including affinity, isotype selection, pharmacokinetics/pharmacodynamics (PK/PD) properties, antibody cross-reactivity across species, and safety. Selection and evaluation of appropriate biomarkers in early preclinical development in "relevant" animal models should allow identification of potential risks and liabilities of an antibody drug candidate to humans and establishment of safe First-In-Human (FIH) dosing strategies. This volume provides a comprehensive review of the topics critical for establishing successful translational strategies for the development of antibody-based therapeutics.
- Contents
- 1. Translational Strategies for Development of Antibody-Based Therapeutics: An Overview -- 2. Discovery Process for Antibody-Based Therapeutics -- 3. Technologies for the Generation of Human Antibodies -- 4. Application of Antibody Engineering in the Development of Next Generation Antibody-Based Therapeutics -- 5. Biophysical Considerations for Development of Antibody-Based Therapeutics -- 6. Considerations in Establishing Affinity Design Goals for Development of Antibody-Based Therapeutics -- 7. Bioanalytical Considerations for Development of Antibody-Based Therapeutics: Pharmacokinetics and Immunogenicity -- 8. Preclinical Considerations for Development of Antibody-Based Therapeutics in Oncology -- 9. Factors Impacting the Tumor Localization and Distribution of Antibody-Based Therapeutics in Oncology -- 10. Preclinical Safety Considerations for the Development of Antibody-Based Therapeutics -- 11. Application of Pharmacokinetic/Pharmacodynamic Modeling in the Development of Antibody-Based Therapeutics -- 12. Application of Population Pharmacokinetic-Pharmacodynamic Approaches in the Design of Translational Strategies for Development of Antibody-Based Therapeutics -- 13. Translational Biomarkers: Essential Tools in Development of Antibody-Based Therapeutics -- 14. Translational Research in Alzheimer’s Disease for Development of Antibody-Based Therapeutics -- 15. Considerations in Manufacturing Process Development for Antibody-Based Therapeutics -- 16. Strategies for Development of Next Generation Antibody-Based Therapeutics -- 17. Immune Complex Therapies for Treatment of Immune Thrombocytopenia -- 18. Application of Bioinformatics Principles for Target Evaluation -- 19. Concluding Remarks.
- Format
- e-Book
- Location
- Online
Fundamentals of antimicrobial pharmacokinetics and pharmacodynamics
https://libcat.nshealth.ca/en/permalink/provcat33695
Alexander A. Vinks, Hartmut Derendorf, Johan W. Mouton, editors.
--New York:
Springer
, c2014.
- Available Online
- View e-Book
- Location
- Online
Over the past decade, significant progress has been made in the theory and applications of pharmacodynamics of antimicrobial agents. On the basis of pharmacokinetic-pharmacodynamic modeling concepts it has become possible to describe and predict the time course of antimicrobial effects under normal and pathophysiological conditions. The study of pharmacokinetic-pharmacodynamic relationships can be of considerable value in understanding drug action, defining optimal dosing regimens, and in makin…
- Available Online
- View e-Book
- Other Authors
- Vinks, Alexander A
- Derendorf, Hartmut
- Mouton, Johan W
- Responsibility
- Alexander A. Vinks, Hartmut Derendorf, Johan W. Mouton, editors
- Place of Publication
- New York
- Publisher
- Springer
- Date of Publication
- c2014
- Physical Description
- 1 online resource (ix, 466 pages)
- ISBN
- 9780387756134 (electronic bk.)
- 9780387756127
- Subjects (LCSH)
- Anti-infective agents - Pharmacokinetics
- Anti-infective agents - Dose-response relationship
- Abstract
- Over the past decade, significant progress has been made in the theory and applications of pharmacodynamics of antimicrobial agents. On the basis of pharmacokinetic-pharmacodynamic modeling concepts it has become possible to describe and predict the time course of antimicrobial effects under normal and pathophysiological conditions. The study of pharmacokinetic-pharmacodynamic relationships can be of considerable value in understanding drug action, defining optimal dosing regimens, and in making predictions under new or changing pre-clinical and clinical circumstances. Not surprisingly, pharmacokinetic-pharmacodynamic modeling concepts are increasingly applied in both basic and clinical research as well as in drug development. Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics is designed as a reference on the application of pharmacokinetic-pharmacodynamic principles for the optimization of antimicrobial therapy, namely pharmacotherapy, and infectious diseases. The reader is introduced to various aspects of the fundamentals of antimicrobial pharmacodynamics, the integration of pharmacokinetics with pharmacodynamics for all major classes of antibiotics, from basic research to clinical situations.
- Contents
- Part I. Basic Concepts and Principles -- 1. Introduction to Pharmacodynamics -- 2. In Vitro and Animal PK/PD Models -- 3. Setting Clinical MIC Breakpoints from a PK/PD Point of View: It Is the Dose That Matters -- 4. Principles of Applied Pharmacokinetic–Pharmacodynamic Modeling -- 5. Pharmacodynamic In Vitro Models to Determine the Effect of Antibiotics -- 6. Population Pharmacokinetic–Pharmacodynamic (PK/PD) Modeling of Anti- infective Agents and Its Applications to Individualized Therapy -- 7. Suppressing Resistance Development -- 8. Drug–Drug Combinations -- Part II. Clinically Oriented Chapters -- 9. Aminoglycosides -- 10. Continuous Infusion of Beta-lactam Antibiotics -- 11. Macrolides and Ketolides -- 12. Glycopeptides -- 13. Clinical Pharmacodynamics of Quinolones -- 14. Pharmacokinetics and Pharmacodynamics of Colistin -- 15. Daptomycin: Pharmacokinetic, Pharmacodynamic, and Dose Optimization -- 16. PK/PD of Oxazolidinones -- 17. Tigecycline.
- Format
- e-Book
- Location
- Online
Fundamentals of Pediatric Drug Dosing
https://libcat.nshealth.ca/en/permalink/provcat40326
Iftekhar Mahmood, Gilbert Burckart, editors.
--Cham:
Springer International Publishing : Imprint: Adis
, c2016.
- Available Online
- View e-Book
- Location
- Online
Focused on pediatric physiology, pharmacology, pharmacokinetics and pharmacodynamics, this book illustrates the differences between the pediatric population and adults; knowledge of extreme importance not only during pediatric drug development but also in the clinical practice. Physicians, nurses, clinical pharmacologists, researchers and healthcare professionals will find this an invaluable resource. With the advent of pediatric exclusivity, and requirements to conduct clinical studies in chil…
- Available Online
- View e-Book
- Other Authors
- Mahmood, Iftekhar
- Burckart, Gilbert
- Responsibility
- Iftekhar Mahmood, Gilbert Burckart, editors
- Place of Publication
- Cham
- Publisher
- Springer International Publishing : Imprint: Adis
- Date of Publication
- c2016
- Physical Description
- 1 online resource (viii, 146 p. : 12 illus. in color)
- ISBN
- 9783319437545
- 9783319437521 (print ed.)
- Subjects (MeSH)
- Pediatrics - methods
- Pharmacokinetics
- Pharmacology - methods
- Dose-Response Relationship, Drug
- Abstract
- Focused on pediatric physiology, pharmacology, pharmacokinetics and pharmacodynamics, this book illustrates the differences between the pediatric population and adults; knowledge of extreme importance not only during pediatric drug development but also in the clinical practice. Physicians, nurses, clinical pharmacologists, researchers and healthcare professionals will find this an invaluable resource. With the advent of pediatric exclusivity, and requirements to conduct clinical studies in children, an emphasis has been placed on finding a safe and efficacious dose of a drug in children. Children are not "small adults", and drug dosing in this population requires special consideration. There are subtle physiological and biochemical differences among neonates, infants, children, adolescents and adults and dosing in pediatrics requires proper understanding of these factors. Furthermore, dosing in children, as in adults, should be based on pharmacokinetic and pharmacodynamic data. This is an evolving area, as pediatric pharmacokinetic studies are becoming mandatory for getting approval of new drugs in this population.
- Contents
- 1. Pediatric Drug Development and the Regulatory Changes that are Creating the Science of Pediatric Dosing -- 2. Pediatric Physiology -- 3. Developmental Pharmacology: Impact on Pharmacokinetics and Pharmacodynamics of Drugs -- 4. Pediatric Clinical Trial Design and Dosing -- 5. Applicaton of Allometric Principles in Pediatric Drug Development -- 6. Population Pharmacokinetics in Pediatric Drug Development -- 7. Scaling Dose-Exposure-Response from Adults to Children -- 8. Applications of Physiologically-Based Pharmacokinetic (PBPK) Models for Pediatric Populations -- 9. Perinatal Pharmacology and Maternal/Fetal Dosing.
- Format
- e-Book
- Location
- Online
Handbook of anticancer pharmacokinetics and pharmacodynamics
https://libcat.nshealth.ca/en/permalink/provcat33329
Michelle A. Rudek, Cindy H. Chau, associate editors ; William D. Figg, Howard L. McLeod, senior editors.
(Second edition)
--New York:
Humana Press
, c2014.
- Available Online
- View e-Book
- Location
- Online
- Available Online
- View e-Book
- Other Authors
- Rudek, Michelle A
- Chau, Cindy H
- Figg, William D
- McLeod, Howard L
- Responsibility
- Michelle A. Rudek, Cindy H. Chau, associate editors ; William D. Figg, Howard L. McLeod, senior editors
- Edition
- Second edition
- Place of Publication
- New York
- Publisher
- Humana Press
- Date of Publication
- c2014
- Physical Description
- 1 online resource (ix, 836 pages)
- Series Title
- Cancer drug discovery and development
- ISBN
- 9781461491354 (electronic bk.)
- 9781461491347
- Subjects (LCSH)
- Antineoplastic agents - Research - Handbooks, manuals, etc
- Antineoplastic Agents - pharmacology
- Antineoplastic Agents - pharmacokinetics
- Contents
- Molecular Targets -- Preclinical Screening for New Anticancer Agents -- Natural Product Screening -- Defining the Starting Dose: Should It Be mg/kg, mg/m2, or Fixed? -- Phase 0 Trials in Oncology -- Phase I Trials in Oncology: Design and Endpoints -- Quantitative Analytical Methods: Development and Clinical Considerations -- Validation and Control of Bioanalytical Methods -- Anticancer Clinical Pharmacology Overview -- Pharmacokinetic Modeling -- Pharmacometrics -- Pharmacodynamic Modeling -- Protein Binding -- Metabolism (Non-CYP Enzymes) -- Pharmacogenomics and Cancer Therapy: Somatic and Germline Polymorphisms -- Cytochrome P450 -- Polymorphisms in Genes of Drug Targets and Metabolism -- DNA Repair: ERCC1, Nucleotide Excision Repair, and Platinum Resistance -- Drug Interactions -- ABC Transporters: Involvement in Multidrug Resistance and Drug Disposition -- Solute Carriers -- High-Throughput Platforms in Drug Metabolism and Transport Pharmacogenetics -- Intrathecal Administration -- Microdialysis -- Regional Drug Delivery for Inoperable Pulmonary Malignancies -- Blood–Brain Barrier and CNS Malignancy -- Radiation and Altering Clinical Pharmacology -- Therapeutic Cancer Vaccines: An Emerging Approach to Cancer Treatment -- Recombinant Immunotoxins -- Monoclonal Antibodies -- Clinical Pharmacology in Pediatrics -- Clinical Pharmacology in the Older Adult -- Organ Dysfunction Trials: Background, Historical Barriers, Progress in Overcoming Barriers, and Suggestions for Future Trials -- Drug Formulations: How these Affects Anticancer Drug -- Nanotechnology in Cancer -- Imaging in Drug Development -- Exposure–Response Relationships of Anticancer Agents: Application in Drug Development and Drug Label -- The Role of Phase III Trials in Modern Drug Development -- Clinical Trial Designs for Approval of New Anticancer Agents -- Clinical Pharmacogenetics.
- Format
- e-Book
- Location
- Online
Handbook of microdialysis : methods, applications, and perspectives
https://libcat.nshealth.ca/en/permalink/provcat27212
[edited by] Ben H.C. Westerink and Thomas Cremers.
(1st ed.)
--Boston, MA:
Elsevier B. V
, c2007.
- Available Online
- View e-Book
- Location
- Online
- Available Online
- View e-Book
- Author
- Westerink, B. H. C
- Other Authors
- Cremers, Thomas
- Responsibility
- [edited by] Ben H.C. Westerink and Thomas Cremers
- Edition
- 1st ed.
- Place of Publication
- Boston, MA
- Publisher
- Elsevier B. V
- Date of Publication
- c2007
- ISBN
- 6610751838 (electronic bk.)
- Subjects (MeSH)
- Brain Chemistry
- Microdialysis - methods
- Contents
- Cover -- Copyright page -- Contents -- List of contributors -- Preface -- Part One -- Section 1: Interpretation and Significance -- Chapter 1.1. What did we learn from microdialysis? -- Chapter 1.2. Microdialysis of glutamate and GABA in the brain: analysis and interpretation -- Chapter 1.3. Insights into glutamate physiology: contribution of studies utilizing in vivo microdialysis -- Chapter 1.4. The validity of intracerebral microdialysis -- Chapter 1.5. Microdialysis in the brain of anesthetized vs. freely moving animals -- Chapter 1.6. Quantitative aspects of brain microdialysis: insights from voltammetric measurements of dopamine next to microdialysis probes -- Section 2: Methods -- Chapter 2.1. New methodological aspects of microdialysis -- Chapter 2.2. Principles of quantitative microdialysis -- Chapter 2.3. Automation of blood and microdialysis sampling: combinatorial pharmacology -- Chapter 2.4. Dopamine-acetylcholine interactions in the brain studied by in vivo microdialysis -- Chapter 2.5. Microdialysis as a platform for multidisciplinary strategies -- Chapter 2.6. Ultraslow microfiltration and microdialysis for in vivo sampling: principle, techniques, and applications -- Section 3: Analytical Chemical Aspects of Microdialysis -- Chapter 3.1. Liquid chromatographic methods used for microdialysis: an overview -- Chapter 3.2. Microdialysis coupled with liquid chromatography/mass spectrometry -- Chapter 3.3. Improvement of the temporal resolution of brain microdialysis: sampling in seconds -- Chapter 3.4. In vivo peptidomics: discovery and monitoring of neuropeptides using microdialysis and liquid chromatography with mass spectrometry -- Part Two -- Section 4: Microdialysis and the Study of Behaviour -- Chapter 4.1. Microdialysis to study the effects of stress on serotonin, corticosterone and behaviour -- Chapter 4.2. Microdialysis of dopamine and norepinephrine during conditioning and operant behaviour -- Chapter 4.3. Microdialysis in the study of behavior reinforcement and inhibition -- Chapter 4.4. Changes in acetylcholine extracellular levels during cognitive processes -- Section 5: CNS Pathology Models -- Chapter 5.1. Microdialysis in genetically altered animals -- Chapter 5.2. The use of microdialysis in neuropsychiatric disease models -- Chapter 5.3. The use of microdialysis for the study of neurological disorders -- Chapter 5.4. Online glucose and lactate monitoring during physiological and pathological conditions -- Chapter 5.5. Microdialysis in pain research -- Section 6: Role of Microdialysis in Drug Development -- Chapter 6.1. The role of microdialysis in drug discovery: focus on antipsychotic agents -- Chapter 6.2. Use of microdialysis in drug discovery and development: industry and regulatory perspectives -- Chapter 6.3. The use of brain microdialysis in antidepressant drug research -- Chapter 6.4. Microdialysis as a method to study blood-brain barrier transport mechanisms -- Chapter 6.5. Assaying protein-unbound drugs using microdialysis techniques -- Chapter 6.6. Microdialysis for characterization of PK/PD relationships -- Chapter 6.7. Application of microdialysis in pharmacokinetic studies -- Section 7: Clinical Applications -- Chapter 7.1. Microdialysis in clinical drug delivery studies -- Chapter 7
- Format
- e-Book
- Location
- Online
Handbook of pediatric HIV care
https://libcat.nshealth.ca/en/permalink/provcat27256
edited by Steven L. Zeichner and Jennifer S. Read.
(2nd ed.)
--Cambridge, UK:
Cambridge University Press
, 2006.
- Available Online
- View e-Book
- Location
- Online
- Available Online
- View e-Book
- Author
- Zeichner, Steven L.
- Other Authors
- Read, Jennifer S.
- Responsibility
- edited by Steven L. Zeichner and Jennifer S. Read
- Edition
- 2nd ed.
- Place of Publication
- Cambridge, UK
- Publisher
- Cambridge University Press
- Date of Publication
- 2006
- Physical Description
- xxx, 871 p.
- ISBN
- 6610458413 (electronic bk.)
- Subjects (MeSH)
- Child
- HIV Infections
- Infant
- Contents
- Cover -- Half-title -- Title -- Copyright -- Dedication -- Contents -- List of Contributors -- List of Abbreviations -- Foreword -- Preface -- Part I Scientific basis of pediatric HIV care -- 1. The scientific basis of pediatric HIV care -- Normal development and physiology of the immune system -- HIV basic virology -- Immunology of pediatric HIV disease -- The clinical virology of pediatric HIV disease -- Natural history of pediatic HIV infection -- Conclusions -- Acknowledgments -- REFERENCES -- 2. The epidemiology of pediatric HIV disease -- Introduction -- HIV/AIDS among children in the USA -- HIV/AIDS among children globally -- Conclusions -- REFERENCES -- Part II General issues in the care of pediatric HIV patients -- 3. Diagnosis of HIV infection in children -- HIV-1 Diagnostic assays -- Diagnosing HIV-1 infection in infants and children -- Diagnosis of non-subtype B HIV-1 infection -- Summary -- Acknowledgments -- REFERENCES -- 4. Prevention of mother-to-child transmission of HIV -- Introduction -- Risk factors for, and interventions to prevent, mother-to-child transmission of HIV -- Strategies for the prevention of mother-to-child transmission of HIV -- Conclusions -- REFERENCES -- 5. Routine pediatric care -- Introduction -- Care of the HIV-exposed infant -- Care of the HIV-infected child -- Summary -- REFERENCES -- 6. Emergency evaluation and care -- Emergency department presentation -- Fever -- Respiratory distress -- Gastrointestinal emergencies -- Neurologic emergencies -- Summary -- REFERENCES -- 7. Adherence to antiretroviral therapy in children and youth -- HIV as a chronic illness -- Assessment of adherence -- Improving adherence -- Conclusion -- REFERENCES -- 8. Adolescents and HIV -- Introduction -- Epidemiology -- Adolescent development -- Counseling and testing -- Prevention -- Care of the HIV-infected adolescent -- Care programs for the HIV-infected adolescent -- Conclusions -- REFERENCES -- 9. Growth, nutrition, and metabolism -- Definitions: malnutrition, growth failure -- Effects of malnutrition -- Routine nutritional assessment -- Causes of malnutrition and associated therapies -- Metabolic abnormalities and associated therapies -- 10. Neurobehavioral function and assessment of children and adolescents with HIV-1 infection -- Clinical presentation of HIV-related CNS disease in children -- Effects of antiretroviral treatment on neurobehavioral function -- Summary -- Acknowledgments -- REFERENCES -- Part III Antiretroviral therapy -- 11. Antiretroviral therapy -- The biology of HIV and antiretroviral therapy -- Antiretroviral agents -- REFERENCES -- 12. Antiretroviral drug Interactions -- Pharmacokinetic drug interactions -- Pharmacodynamic drug interactions -- Conclusions -- Acknowledgments -- REFERENCES -- 13. Metabolic complications of antiretroviral therapy in children -- Introduction -- Fatredistribution syndrome, lipid abnormalities, and insulin resistance.
- Format
- e-Book
- Location
- Online
HIV and psychiatry : a training and resource manual
https://libcat.nshealth.ca/en/permalink/provcat27220
edited by Kenneth Citron, Marie-Josée Brouillette, Alexandra Beckett.
(2nd ed.)
--Cambridge, UK:
Cambridge University Press
, c2005.
- Available Online
- View e-Book
- Location
- Online
- Available Online
- View e-Book
- Author
- Citron, Kenneth
- Other Authors
- Brouillette, Marie-Josée
- Beckett, Alexandra
- Responsibility
- edited by Kenneth Citron, Marie-Josée Brouillette, Alexandra Beckett
- Edition
- 2nd ed.
- Place of Publication
- Cambridge, UK
- Publisher
- Cambridge University Press
- Date of Publication
- c2005
- Physical Description
- xiv, 346 p.
- ISBN
- 6610202885 (electronic bk.)
- Subjects (MeSH)
- HIV infections - psychology
- Contents
- Cover -- Half-title -- Title -- Copyright -- Dedication -- Contents -- Contributors -- Preface -- 1 Medical overview -- Introduction -- What is the epidemiology of HIV infection? -- World -- USA -- How is HIV transmitted? -- Sexual -- Injection drug use -- Maternal...fetal -- Other considerations -- What is the pathogenesis of HIV infection? -- How is a diagnosis of HIV infection made, and how is HIV infection classified? -- What are the clinical manifestations of HIV infection? -- Primary HIV infection -- Latency period -- Oral and skin manifestations -- Pulmonary manifestations -- Gastrointestinal manifestations and multi-organ system disease -- Neurocognitive and neurologic manifestations -- What is involved in the initial evaluation of a patient with HIV disease? -- History -- Physical examination -- Laboratory studies -- How is HIV infection managed? -- Antiretroviral therapy -- Opportunistic infection prophylaxis -- Conclusion -- Suggested reading -- Web Sites -- 2 Cognitive disorders in people living with HIV disease -- Introduction -- What causes the cognitive dysfunction associated with HIV infection? -- What nomenclature is used to describe the neurobehavioral disorders that occur in HIV infection? -- What is the prevalence of HADC and MCMD? -- What are the characteristics of HACM? -- What are the characteristics of HIV-associated minor cognitive motor disorder (MCMD)? -- What is the course of illness? -- What is the morbidity associated with HIV-related neurocognitive impairment? -- What is the relationship between cognitive complaints and depression? -- What is the treatment approach when patients have symptoms of depression and MCMD? -- When should a psychiatrist consider neuropsychological testing? -- What are the characteristics of HIV-associated dementia complex (HADC)? -- What are the risk factors for HADC? -- Which elements in this history are important in establishing the diagnosis? -- What is the differential diagnosis and how can the physician narrow it? -- What other investigations are necessary to establish a diagnosis? -- Could the patient's symptoms be caused by major depression? -- Could the symptoms be caused by the substances that the patient is using? -- What mental status screening and assessment tools should be used? -- What other staging system can be used to describe the cognitive changes in HIV disease? -- Are there specific treatments for HACM? -- What can be done for the fatigue and apathy? -- What impact does HADC have on behavior? -- How should behavioral symptoms associated with HADC be treated? -- Are there nonpharmacological interventions that should be considered in the management of HADC? -- What is the prognosis for a person presenting with HADC? -- Conclusion -- References -- 3 General principles of pharmacotherapy for the patient with HIV infection -- Introduction -- What is the main mechanism responsible for interactions between antiretrovirals and ... -- How are antiretrovirals metabolized and how can they influence the bioavailability of psychotropic medications? -- What are the clinical implications of these pharmacokinetic interactions? -- What medications used in HIV care (other than antiretrovira
- Format
- e-Book
- Location
- Online
Imaging Infections : From Bench to Bedside
https://libcat.nshealth.ca/en/permalink/provcat41750
Sanjay K. Jain, editor.
--Cham:
Springer
, 2017.
- Available Online
- View e-Book
- Location
- Online
This books brings together multi-disciplinary expertise to provide comprehensive information about molecular imaging of infectious diseases. Also described are the development of new imaging technologies for infectious disease and their translation to the clinic. The overall goal of Imaging Infections: From Bench to Bedside is to spur interest and innovation in this emerging field. We anticipate that these technologies will not only allow unique insights into understanding pathogenesis of infec…
- Available Online
- View e-Book
- Other Authors
- Jain, Sanjay K
- Responsibility
- Sanjay K. Jain, editor
- Place of Publication
- Cham
- Publisher
- Springer
- Date of Publication
- 2017
- Physical Description
- 1 online resource (xi, 261 pages) : 70 illus., 47 illus. in color
- ISBN
- 9783319545929
- 9783319545905 (print ed.)
- Subjects (MeSH)
- Communicable Diseases - diagnostic imaging
- Molecular Imaging
- Abstract
- This books brings together multi-disciplinary expertise to provide comprehensive information about molecular imaging of infectious diseases. Also described are the development of new imaging technologies for infectious disease and their translation to the clinic. The overall goal of Imaging Infections: From Bench to Bedside is to spur interest and innovation in this emerging field. We anticipate that these technologies will not only allow unique insights into understanding pathogenesis of infections but also expedite bench-to-bedside translation of new therapeutics. While molecular imaging is already in common use in the clinic, this book demonstrates how it could also become a valuable tool for clinical studies, patient care, public health, and for enabling precision medicine for infectious diseases.
- Contents
- Introduction -- Clinical Imaging -- Optical Imaging -- Radiochemistry -- Imaging the Host Response -- Bacterial Imaging -- Fungal Infections -- Neuroimaging -- Pharmacokinetic and Pharmacodynamics Relationships -- Biodistribution and Pharmacokinetics of Antimicrobials -- Image Analyses -- Imaging in the Developing World.
- Format
- e-Book
- Location
- Online
Locoregional Radionuclide Cancer Therapy : Clinical and Scientific Aspects
https://libcat.nshealth.ca/en/permalink/provcat46497
Franklin C.L. Wong, editor.
--Cham:
Springer
, c2021.
- Available Online
- View e-Book
- Access
- NEW Springer 2021
- Location
- Online
This book reviews locoregional radionuclide cancer therapies (LRCT). Proving an increasingly viable alternative to radiotherapy, radionuclide therapy includes a diversity of choices of well characterized biochemical and physiologic target molecules. The delivery and retention of radionuclides may be monitored by advanced imaging for exact tissue localization and for real-time dosimetry to enable personalized precision medicine. Radiopharmaceuticals in human cancer therapies are typically delive…
- Available Online
- View e-Book
- Other Authors
- Wong, Franklin C.L.
- Responsibility
- Franklin C.L. Wong, editor
- Place of Publication
- Cham
- Publisher
- Springer
- Date of Publication
- c2021
- Physical Description
- 1 online resource (xii, 268 p.) : 76 illus., 56 illus. in color
- ISBN
- 9783030562670
- 9783030562663 (Print ed.)
- 9783030562687 (Print ed.)
- 9783030562694 (Print ed.)
- Subjects (MeSH)
- Neoplasms - radiotherapy
- Radiopharmaceuticals - therapeutic use
- Radiotherapy Dosage
- Radiotherapy - methods
- Specialty
- Medical Oncology
- Radiotherapy
- Abstract
- This book reviews locoregional radionuclide cancer therapies (LRCT). Proving an increasingly viable alternative to radiotherapy, radionuclide therapy includes a diversity of choices of well characterized biochemical and physiologic target molecules. The delivery and retention of radionuclides may be monitored by advanced imaging for exact tissue localization and for real-time dosimetry to enable personalized precision medicine. Radiopharmaceuticals in human cancer therapies are typically delivered in systemic routes but can also be designed for locoregional routes to harness pharmacokinetic advantages of higher payload and lower systemic toxicities. This book explores the latest advancements and clinical considerations of the locoregional approach. Throughout the chapters, the clinical and scientific bases of cancer treatment and the locoregional use of radionculides are explored. Mathematical models of radiation dosimetry of locoregional radionculdies on tissues are studied using common models for multiple commercially available radionuclides. Rodent and canine tumor models of LRCT are compared for selected radionuclides and radiopharmaceuticals. The practical aspects of radiopharmaceuticals production, marketing, transport, as well as radiation protection are reviewed. Finally, the combination of LRCT with immunotherapy and other cancer therapies and prospective future use of LRCT are discussed. This is a guide for practicing nuclear physicians, interventional radiologists, radiation oncologists, radiation scientists, veterinarians and oncologists to expand their knowledge base and to prepare for designing locoregional radionuclide cancer therapies in animals and in humans.
- Contents
- 1. Human Cancer: Epidemiology, Hallmarks, and Defense Strategies -- 2. Cancer Treatment Modalities Systemic and Locoregional Approaches: Challenges and Opportunities of Multidisciplinary Approaches -- 3. Cancer Radiotherapy: General Considerations and Human Radiobiology -- 4. Radionuclide Cancer Therapy: Unsealed Alpha- and Beta-Emitters - 5. Locoregional Therapy: Cancer Interventions with and Without Radionuclides -- 6. Radiation Dosimetry Considerations of Locoregional Radionuclide Cancer Therapy -- 7. Voxel-Based Targeted Radionuclide Therapy Dosimetry -- 8. Locoregional Unsealed Radionuclide Cancer Therapy: Experimental Findings -- 9. Animal Cancer Therapy Models: Ready Translation to Humans -- 10. An Overview of the Regulations of Radiopharmaceuticals -- 11. Locoregional Radionuclide Cancer Therapy (LRCT) Using Sealed and Unsealed Radionuclides.
- Access
- NEW Springer 2021
- Format
- e-Book
- Location
- Online
Locoregional tumor therapy
https://libcat.nshealth.ca/en/permalink/provcat33613
Eric Van Cutsem, Thomas J. Vogl, Vranco Orsi, Alberto Sobrero, editors.
--Berlin:
Springer
, c2015.
- Available Online
- View e-Book
- Location
- Online
- Available Online
- View e-Book
- Other Authors
- Cutsem, Eric van
- Vogl, Thomas J
- Orsi, Franco
- Sobrero, Alberto
- Responsibility
- Eric Van Cutsem, Thomas J. Vogl, Vranco Orsi, Alberto Sobrero, editors
- Place of Publication
- Berlin
- Publisher
- Springer
- Date of Publication
- c2015
- Physical Description
- 1 online resource (vi, 161 pages)
- ISBN
- 9783642365720 (electronic bk.)
- 9783642365713
- Subjects (MeSH)
- Neoplasms - drug therapy
- Ablation Techniques
- Subjects (LCSH)
- Tumors - Treatment
- Contents
- 1. Introduction -- Part I. Basics of Regional Tumor Therapies -- 2. Pharmacokinetic Aspects of Regional Tumor Therapy -- 3. Embolization Materials, Catheters, and Intra-arterial Ports -- Part II. Intra-arterial Therapies: Liver -- 4. HCC -- 5. CRC Liver Metastases -- 6. Liver Metastases of Neuroendocrine Tumors and CCC -- 7. Liver Metastases of Other Indications -- Part III. Intra-arterial Therapies: Lung, Head and Neck -- 8. Chemoembolization of Lung Tumors -- 9. Head and Neck -- Part IV. Thermoablation -- 10. Radiofrequency Ablation for Treating Malignant Tumors to the Liver -- 11. Radiofrequency Ablation for Treating Malignant Tumors to the Lungs.
- Format
- e-Book
- Location
- Online
Locoregional Tumor Therapy
https://libcat.nshealth.ca/en/permalink/provcat43086
Eric Van Cutsem, Thomas J. Vogl, Franco Orsi, Alberto Sobrero, editors.
(Second edition)
--Cham:
Springer
, c2018.
- Available Online
- View e-Book
- Location
- Online
This book presents, in condensed form, the clinical results achieved by means of various locoregional tumor therapies employed for different indications. In so doing, it will allow the reader to rapidly retrieve the information on indications and effectiveness that is required for optimal integration of these highly effective therapies into modern, complex treatment strategies. The renaissance in locoregional tumor therapies is an ongoing process. New chemotherapeutic schedules, especially for …
- Available Online
- View e-Book
- Other Authors
- Van Cutsem, Eric
- Vogl, Thomas J.
- Orsi, Franco
- Sobrero, Alberto
- Responsibility
- Eric Van Cutsem, Thomas J. Vogl, Franco Orsi, Alberto Sobrero, editors
- Edition
- Second edition
- Place of Publication
- Cham
- Publisher
- Springer
- Date of Publication
- c2018
- Physical Description
- 1 online resource (viii, 274 p.) : 7 illus., 4 illus. in color
- ISBN
- 9783319699479
- 9783319699462 (print ed.)
- 9783319699486 (print ed.)
- Specialty
- Medical Oncology
- Abstract
- This book presents, in condensed form, the clinical results achieved by means of various locoregional tumor therapies employed for different indications. In so doing, it will allow the reader to rapidly retrieve the information on indications and effectiveness that is required for optimal integration of these highly effective therapies into modern, complex treatment strategies. The renaissance in locoregional tumor therapies is an ongoing process. New chemotherapeutic schedules, especially for liver and lung tumors, have been developed during the past few years. Other targeted therapies, such as radioembolization, microwave ablation, and HIFU techniques, and new pharmaceuticals for intra-arterial therapy have been developed and implemented in clinical practice. Furthermore, the advantages of unlimited combination of starch microspheres with various antitumor agents, supported by effective ischemia, have been increasingly exploited. The second edition of this book reflects these advances and includes entirely new chapters on the role of intraperitoneal perfusion in treating peritoneal carcinomatosis and the use of limb perfusion. Locoregional Tumor Therapy will be invaluable for all practitioners who work with cancer patients.
- Contents
- Part I. Basics of Regional Tumor Therapies -- 1. Pharmacokinetic Aspects of Regional Tumor Therapy -- 2. Embolization Materials, Catheters, and Intra-Arterial Ports -- Part II. Intra-arterial Therapies: Liver -- 3. HCC -- 4. Indications for Locoregional Tumor Therapies: CRC Liver Metastases -- 5. Liver Metastases of Neuroendocrine Tumors and CCC -- 6. Liver Metastases of Other Indications -- Part III. Intra-arterial Therapies: Lung, Head and Neck - 7. Chemoperfusion and Chemoembolization of Malignant Pulmonary Tumors -- 8. Head and Neck -- Part IV. Thermoablation -- 9. Thermal Ablation for Treating Malignant Tumors to the Liver -- 10. Radiofrequency Ablation for Treating Malignant Tumors to the Lungs -- Part V. Other locoregional Tumor Therapies -- 11. Treatment of Peritoneal Carcinomatosis -- 12. Melanoma.
- Format
- e-Book
- Location
- Online
Oral Anticoagulation Therapy : Cases and Clinical Correlation
https://libcat.nshealth.ca/en/permalink/provcat41753
Kathryn Kiser, editor.
--Cham:
Springer
, 2017.
- Available Online
- View e-Book
- Location
- Online
This case-based title reviews anticoagulation management strategies available for a wide variety of clinical scenarios. Designed to aid providers of direct patient care on complex clinical decisions regarding appropriate evidence-based therapy options, patient and agent related variables to consider, as well as expert opinion on the topic. Oral Anticoagulation Therapy: Cases and Clinical Correlation will provide clinicians and trainees with clear clinical cases, commentary, and resources to dev…
- Available Online
- View e-Book
- Other Authors
- Kiser, Kathryn
- Responsibility
- Kathryn Kiser, editor
- Place of Publication
- Cham
- Publisher
- Springer
- Date of Publication
- 2017
- Physical Description
- 1 online resource (x, 313 pages) : 6 illus., 2 illus. in color
- ISBN
- 9783319546438
- 9783319546414 (print ed.)
- Subjects (MeSH)
- Administration, Oral
- Anticoagulants - therapeutic use
- Hemorrhage - drug therapy
- Vascular Diseases - drug therapy
- Warfarin - therapeutic use
- Abstract
- This case-based title reviews anticoagulation management strategies available for a wide variety of clinical scenarios. Designed to aid providers of direct patient care on complex clinical decisions regarding appropriate evidence-based therapy options, patient and agent related variables to consider, as well as expert opinion on the topic. Oral Anticoagulation Therapy: Cases and Clinical Correlation will provide clinicians and trainees with clear clinical cases, commentary, and resources to develop their knowledge base, problem-solving skills, and ability to practically apply new knowledge to a variety of clinical situations. Resources provided in cases include valuable figures, tables, and key points designed for the reader to be able to utilize at the point of care.
- Contents
- Part I: Introduction -- 1. Introduction -- Part II: Atrial Fibrillation -- 2. CHA2DS2-VASc and HAS-BLED Risk Stratification Tools -- 3. Male with Priority of Ischemic Stroke Reduction -- 4. Choosing an Anticoagulant in an Elderly Patient -- 5. Patient with Prior History of GI Hemorrhage -- 6. Patients with a History of Intracranial Hemorrhage -- 7. Concerns with Anticoagulant Adherence -- 8. Oral Anticoagulants in Stable Moderate Chronic Kidney Disease -- 9. Oral Anticoagulants in Severe Renal Dysfunction -- 10. Oral Anticoagulants in Patients with Variable Renal Function -- 11. Patient with Concomitant Stable Coronary Artery Disease -- 12. Patient with Concomitant Acute Venous Thromboembolism -- 13. Patient with Concomitant Mitral Valve Stenosis -- 14. Patient with Concomitant Aortic Valve Stenosis -- Part III: Warfarin Management -- 15. Best Practice for Switching Stable Warfarin Patients -- 16. Patient-Centered Strategies for Improving Warfarin Management -- Part IV: Venous Thromboembolism (VTE) -- 17. Provoked Versus Unprovoked Venous Thromboembolism -- 18. Venous Thromboembolism (VTE) Prophylaxis in Hip and Knee Replacement Surgery -- 19. Venous Thromboembolism (VTE) Prophylaxis in the Intensive Care Unit (ICU) -- 20. VTE and Recent Drug Eluting Stent (DES) Placement -- 21. Acute VTE in a Patient with Moderate Chronic Kidney Disease -- 22. Oral Anticoagulation and Duration in Recurrent Venous Thromboembolism (VTE) -- 23. Pulmonary Embolism (PE) with Thrombolytic Therapy -- Part V: Acute Coronary Syndrome (ACS) -- 24. Patient on Oral Anticoagulant Presenting with ACS -- 25. Oral Anticoagulant Therapy Post-Percutaneous Coronary Intervention -- 26. ST-Segment Elevation Myocardial Infarction (Lytic Candidate) on Oral Anticoagulant -- 27. ACS with Bypass Surgery -- Part VI: Drug Interactions -- 28. Anticoagulant Drug-Drug Interactions with CYP 3A4 Inhibitors -- 29. Significance of P-glycoprotein (P-gp) Drug-Drug Interactions -- 30. Considerations with Pharmacodynamic Drug-Drug Interactions -- 31. Management of Direct Oral Anticoagulants with Mixed P-gp/3A4 Drug-Drug Interactions -- 32. Pharmacokinetic Drug-Drug Interactions with Warfarin -- Part VII: Special Populations -- 33. Chronic Pain Management with Anticoagulation -- 34. Anticoagulation Management in Atrial Fibrillation Catheter Ablation -- 35. Anticoagulation Management Considerations for Mechanical Valves -- 36. Management of Antiphospholipid Antibody Syndrome -- 37. Venous Thromboembolism and Pregnancy -- 38. Venous Thromboembolism in Active Malignancy -- 39. Anticoagulation Management in Patients Undergoing Gastric Bypass Procedures -- 40. Patient Presenting with Minor Bleeding -- 41. Patient Presenting with Major, Life-Threatening Bleeding -- 42. Overdose of Dabigatran.
- Format
- e-Book
- Location
- Online
